loading
Schlusskurs vom Vortag:
$1.43
Offen:
$1.46
24-Stunden-Volumen:
48,252
Relative Volume:
0.20
Marktkapitalisierung:
$112.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.4824
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
-5.63%
1M Leistung:
-18.38%
6M Leistung:
-35.47%
1J Leistung:
+17.97%
1-Tages-Spanne:
Value
$1.44
$1.52
1-Wochen-Bereich:
Value
$1.415
$1.83
52-Wochen-Spanne:
Value
$1.12
$4.20

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name
Firmenname
Inhibikase Therapeutics Inc
Name
Telefon
678-392-3419
Name
Adresse
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Name
Mitarbeiter
16
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
IKT's Discussions on Twitter

Vergleichen Sie IKT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IKT
Inhibikase Therapeutics Inc
1.51 106.31M 0 -19.57M -17.24M -3.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
374.46 93.98B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
435.00 57.53B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.94 59.67B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
638.90 40.50B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
289.75 34.26B 3.81B -644.79M -669.77M -6.24

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-12 Herabstufung H.C. Wainwright Buy → Neutral

Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten

pulisher
Aug 11, 2025

Key metrics from Inhibikase Therapeutics Inc.’s quarterly dataSwing Watchlist With Tight Stop Placement - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

What indicators show strength in Inhibikase Therapeutics Inc.Free Real Market Momentum Signal Generator - Newser

Aug 11, 2025
pulisher
Aug 11, 2025

Automated trading signals detected on Inhibikase Therapeutics Inc.Free Momentum Based Equity Trading Plan - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

Visual trend scoring systems applied to Inhibikase Therapeutics Inc.Entry Confirmation Using Short-Term Forecasting - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Visual analytics tools that track Inhibikase Therapeutics Inc. performanceReversal Pattern Insights with Entry Tips - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Chart based analysis of Inhibikase Therapeutics Inc. trendsDaily Entry Opportunity Forecasting Tool - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

How high can Inhibikase Therapeutics Inc. stock goMonthly Long-Term Market Recap and Summary - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Risk vs reward if holding onto Inhibikase Therapeutics Inc.Tactical Trade Setup With Entry Optimizer - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Using fundamentals and technicals on Inhibikase Therapeutics Inc.Top Stock Picks with Forecast Accuracy - Newser

Aug 09, 2025
pulisher
Aug 08, 2025

What risks could impact Inhibikase Therapeutics Inc. stock performanceFree Weekly Potential Breakout Stock List - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Inhibikase Therapeutics Inc. recovery potential after sell offSmart Risk Strategy with Entry Optimization - Newser

Aug 08, 2025
pulisher
Aug 07, 2025

How Inhibikase Therapeutics Inc. stock performs during market volatilitySafe Entry Screening with Data Backed Analysis - Newser

Aug 07, 2025
pulisher
Aug 06, 2025

Real time pattern detection on Inhibikase Therapeutics Inc. stockChart Driven Opportunity Scanner with Alerts - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Published on: 2025-08-06 00:58:01 - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

How institutional ownership impacts Inhibikase Therapeutics Inc. stockPortfolio Allocation Strategy for Stability - Newser

Aug 06, 2025
pulisher
Aug 04, 2025

Published on: 2025-08-04 16:30:58 - metal.it

Aug 04, 2025
pulisher
Aug 03, 2025

New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Free AI Driven Buy Alert Trade Blueprint - Newser

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Inhibikase Therapeutics Inc. stockMarket-leading capital gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Inhibikase Therapeutics Inc. compare to its industry peersOutstanding capital growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Inhibikase Therapeutics Inc. stock overvalued or undervaluedFastest return on investment - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Inhibikase Therapeutics Inc. stockConsistent high-performance stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Inhibikase Therapeutics Inc. stock expected to show significant growthBuild a portfolio that outperforms the market - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Inhibikase Therapeutics Inc.Unlock powerful investment tools for free - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Inhibikase Therapeutics Inc. stockDiscover market opportunities with expert help - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Candlestick signals on Inhibikase Therapeutics Inc. stock todayFree Early Breakout Entry Point Notifications - newser.com

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Inhibikase Therapeutics Inc. stock price move sharplyIdentify winners with top-tier analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What drives Inhibikase Therapeutics Inc. stock priceMaximize gains with data-driven trading alerts - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What are Inhibikase Therapeutics Inc. company’s key revenue driversStay informed with daily expert analysis - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCAQ) Head to Head Comparison - Defense World

Aug 02, 2025
pulisher
Aug 01, 2025

Published on: 2025-08-01 22:50:53 - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

Intraday pattern recognizer results for Inhibikase Therapeutics Inc.ROI Focused Watchlist with Trade Confidence - Newser

Aug 01, 2025

Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$79.19
price up icon 1.02%
$36.19
price down icon 3.70%
$28.25
price down icon 1.43%
$112.89
price up icon 3.05%
$109.26
price down icon 2.15%
biotechnology ONC
$289.75
price up icon 0.54%
Kapitalisierung:     |  Volumen (24h):